Verve Therapeutics, Inc. (VERV) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VERV currently has 88.8M outstanding shares. with limited dilution risk as only 13.6M additional shares (15.3%) are authorized for issuance. The company has diluted shareholders by 10.21% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 25, 2025 |
POS AM filing: Post-Effective Amendment to withdraw and remove from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. |
89M | 14M |
| May 14, 2025 |
10-Q filing | 88.8M shares outstanding |
89M | 14M |
| Feb 27, 2025 |
10-K filing | 84.7M shares outstanding |
85M | 14M |
| Feb 27, 2025 |
POS AM filing: The company is filing a POS AM to register the offering and sale of up to $500,000,000 in the aggregate of debt securities, common stock, and preferred stock from time to time in one or more offerings. |
89M | 14M |
| Nov 05, 2024 |
10-Q filing | 84.6M shares outstanding |
85M | 14M |
| Aug 08, 2024 |
10-Q filing | 84.2M shares outstanding |
84M | 14M |
| May 08, 2024 |
10-Q filing | 83.1M shares outstanding |
83M | 14M |
| Feb 27, 2024 |
10-K filing | 83.6M shares outstanding |
84M | 14M |
| Nov 07, 2023 |
10-Q filing | 63.2M shares outstanding |
63M | 14M |
| Aug 10, 2023 |
10-Q filing | 62.0M shares outstanding |
62M | 14M |
| May 15, 2023 |
10-Q filing | 61.8M shares outstanding |
62M | 14M |
| Mar 02, 2023 |
10-K filing | 61.8M shares outstanding |
62M | 14M |
| Nov 07, 2022 |
10-Q filing | 57.2M shares outstanding |
57M | 14M |
| Aug 09, 2022 |
10-Q filing | 59.9M shares outstanding |
60M | 14M |
| May 10, 2022 |
10-Q filing | 48.7M shares outstanding |
49M | 14M |
| Mar 14, 2022 |
10-K filing | 48.6M shares outstanding |
49M | 14M |
| Nov 10, 2021 |
10-Q filing | 48.2M shares outstanding |
48M | 14M |
| Jun 14, 2021 |
S-1/A filing: This S-1/A filing details an offering of 11,800,000 shares of common stock, with an option for underwriters to purchase an additional 1,770,000 shares. The company intends to use the net proceeds for research and development and general corporate purposes. |
44M | 14M |
| May 28, 2021 |
S-1 filing: S-1 filing for an initial public offering of common stock. |
31M | 0 |